NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 9, 2017

Primary Completion Date

July 24, 2018

Study Completion Date

November 28, 2018

Conditions

Neurogenic Orthostatic HypotensionMultiple System Atrophy (MSA) With Orthostatic HypotensionPure Autonomic FailureParkinson DiseaseHypotension, OrthostaticOrthostatic HypotensionPure Autonomic Failure With Orthostatic HypotensionParkinson Disease With Orthostatic Hypotension

Interventions

DRUG

TD-9855

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (6)

10016

Theravance Biopharma Investigational Site, New York

37232

Theravance Biopharma Investigational Site, Nashville

48334

Theravance Biopharma Investigational Site, Farmington Hills

75390

Theravance Biopharma Investigational Site, Dallas

90806

Theravance Biopharma Investigational Site, Long Beach

08009

Theravance Biopharma Investigational Site, Berlin